Abstract
Background: The disease course of inflammatory bowel disease (IBD) following treatment with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to examine the disease course of IBD in patients treated with GLP-1 based therapies compared with treatment with other antidiabetics. Methods: Using nationwide Danish registries, we identified patients with IBD and type 2 diabetes who received antidiabetic treatment between 1 January 2007 and 31 March 2019. The primary outcome was a composite of the need for oral corticosteroids, tumour necrosis factor-α inhibitors, IBD-related hospitalisation, or IBD-related surgery. In the setting of a new-user active comparator design, we used Poisson regression to estimate incidence rate ratios (IRR) comparing treatment with GLP-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors with other antidiabetic therapies. The analyses were adjusted for age, sex, calendar year, IBD severity, and metformin use. Findings: We identified 3751 patients with a diagnosis of IBD and type 2 diabetes and with a prescription of an antidiabetic drug (GLP-1 receptor agonists/DPP-4 inhibitors: 982 patients; other antidiabetic treatment: 2769 patients). The adjusted IRR of the composite outcome was 0·52 (95% CI: 0·42–0·65) for patients exposed to GLP-1 receptor agonists/DPP-4 inhibitors compared with patients exposed to other antidiabetics. Interpretation: In patients with IBD and type 2 diabetes, we observed a lower risk of adverse clinical events amongst patients treated with GLP-1 based therapies compared with treatment with other antidiabetics. These findings suggest that treatment with GLP-1 based therapies may improve the disease course of IBD.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 100979 |
Tidsskrift | EClinicalMedicine |
Vol/bind | 37 |
Antal sider | 8 |
DOI | |
Status | Udgivet - jul. 2021 |
Bibliografisk note
Funding Information:The study was funded by the Novo Nordisk Foundation [grant number NNF16OC0022586 and NNF17OC0029768] and The Danish National Research Foundation [grant number DNRF148].
Funding Information:
Funding: The study was funded by the Novo Nordisk Foundation [grant number NNF16OC0022586 and NNF17OC0029768] and The Danish National Research Foundation [grant number DNRF148].
Publisher Copyright:
© 2021 The Authors